Cytomegalievirus bei Nierentransplantation – Diagnose, Prävention und Management

Das Cytomegalievirus (CMV) ist die häufigste virale Infektion, die nach der Transplantation solider Organe zu schwerwiegenden Komplikationen führen kann. Eine deutsche Expertengruppe hat nun die im Jahr 2013 veröffentlichten internationalen Konsensus-Leitlinien zu CMV bei Transplantation solider Organe zusammengefasst und bewertet.

Schlüsselwörter

CMV-Diagnose - CMV-Prävention - CMV-Therapie

Key Words

diagnosis of CMV - prevention of CMV - treatment of CMV

• Literaturverzeichnis

• 1 Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213
• 2 Boivin G, Goyette N, Farhan M et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53: 208-213
• 3 Brennan DC, Legendre C, Patel D et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453-2462
• 4 Cervera C, Fernandez-Ruiz M, Valledor A et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis 2011; 13: 598-607
• 5 Dickenmann MJ, Cathomas G, Steiger J et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71: 764-767
• 6 Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157-161
• 7 Ekberg H, Bernasconi C, Noldeke J et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004-2010
• 8 Fachinformation. Valcyte® 50 mg / ml Pulver zur Herstellung einer Lösung zum Einnehmen (Mono). Stand: April 2013. FachInfo-Service; 2013
• 9 Fortun J, Martin-Davila P, Pascual J et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12: 397-405
• 10 Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation 2013; 95: 1015-1020
• 11 Halme L, Lempinen M, Arola J et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS 2008; 116: 99-106
• 12 Hodson EM, Ladhani M, Webster AC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2 CD003774
• 13 Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431
• 14 Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983
• 15 Kotton CN, Kumar D, Caliendo AM et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360
• 16 Kranz B, Vester U, Wingen AM et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12: 474-478
• 17 Lautenschlager I, Halme L, Hockerstedt K et al. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8: 21-30
• 18 Le Page AK, Jager MM, Iwasenko JM et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56: 1018-1029
• 19 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097
• 20 McLaughlin K, Wu C, Fick G et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002; 74: 813-816
• 21 Owers DS, Webster AC, Strippoli GF et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2 CD005133
• 22 Ozaki KS, Camara NO, Nogueira E et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675-680
• 23 Pescovitz MD. Prevention and treatment of cytomegalovirus disease in solid organ transplant recipients: the clinical and economic impact of evolving strategies. Introduction. Am J Health Syst Pharm 2003; 60 (Suppl. 08) S3-S4
• 24 Pilmore H, Pussell B, Goodman D. KHA-CARI guideline: cytomegalovirus disease and kidney transplantation. Nephrology 2011; 16: 683-687
• 25 Ritter M, Schmidt T, Dirks J et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013; 43: 1099-1108
• 26 Robert Koch-Institut. Epidemiologisches Bulletin. Nr. 3, Januar 2014
• 27 Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Intern 2004; 66: 329-337
• 28 Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174
• 29 San Juan R, Aguado JM, Lumbreras C et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875-882
• 30 Sester M, Gärtner BC, Sester U. Monitoring of CMV-specific T-cell levels after organ transplantation. J Lab Med 2008; 32: 121-130
• 31 Smith JM, Corey L, Bittner R et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586
• 32 Stitt N. Infection in the Transplant Recipient. Medscape Online; 2003. http://www.medscape.com/viewarticle/451788 Letzter Zugriff: 18. 02. 2015
• 33 Tong CY, Bakran A, Peiris JS et al. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002; 74: 576-578
• 34 van Son WJ, de Maar EF, van Der Bij W et al. Overcoming the problem of cytomegalovirus infection after organ transplantation: calling for Heracles?. Intervirology 1999; 42: 285-290
• 35 Westall GP, Michaelides A, Williams TJ et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190: 1076-1083
• 36 Witzke O, Hauser IA, Bartels M et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93: 61-68